Effect of serum copper concentration and ceruloplasmin on lipid parameters leading to increased propensity to cardiovascular risk

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 2, Issue 2, 2011, Pages 558-563

  Joshi, Vivek R ^a   Mallick, Ayaz K ^a   Manjunatha Goud, B K ^a   Maradi, Ravindra ^b   Reddy, Maheshwar G ^b   Tey, Raghavendra ^c   Shorey, Gaurav ^a  

^a MELAKA MANIPAL MEDICAL COLLEGE   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

^c KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Atherosclerosis; Ceruloplasmin; Dyslipidemia; Hypothyroidism; Low density lipoprotein cholesterol; Serum copper

Indexed keywords

CERULOPLASMIN; CHOLESTEROL; COPPER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CERULOPLASMIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COPPER BLOOD LEVEL; EUTHYROIDISM; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PROTEIN TRANSPORT; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79955534118     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Henkin RI. Med Clin North Am 1976; 60:779-97.
2. Textbook of medical physiology Guyton and hall 934-935.
3. Hatano S, Nishi Y, Usui T. Am J Gin Nutr 1983; 37: 457-60.
4. Hatano S, Nishi Y, Usui T. Am J Clin Nutr l982; 35: l20-.6.
5. An Alturfan, E Zengin, N Dariyerli, EE Alturfan, et al. Folia Biological Paha 2007; 53: 183, 6.
6. Katsuaki Aihara, MD et al. Am J Clin Nutr 1984; 13: 26-35.
7. Beard JL, Brigham DE, Kelley SK, Green MH. J Nutr 1998; 128: 1401-8.
8. Olin KL, Walter RM, Keen CL. Am J Clin Nutr 1994; 59: 654-8.
9. Aspin N, Sass-Korstak A, Copper. In; Bronner F, Coburn JW, eds.New York, NY: Academic Press, 1981: 59:92.
10. Carl A, Burtis and Edward R. Ashwood. In Teitz textbook of clinical chemistry. Published by W. B. Saunders Company. India. 2006.
11. Company leaflet, Roche Diagnostic Corporation, Indianapolis, USA.
12. Zak. B and Landers JM. J Clin Path 1958; 29: 590.
13. Ceruloplasmin: Company leaflet: COBAS INTEGRA; Roche Diagnostics Corporation, Indianapolis, USA.
14. Science. 1977; 198: 595-596.
15. Rodo M, Czonkowska A, Pulawska M, Swiderska M, Tarnacka B, and Wehr H. Eur J Neurol 2000; 7: 491-494.
16. Zhu Q, Anderson GW, Mucha GT, Parks EJ, Metkowski JK, and Mariash CN. Endocrinology 2000; 146: 3343-3350.
17. Freake H, Schwartz H, Oppenheimmer J. Endocrinology 1989; 125: 2868-2878.
18. Hellstrom L, Wahrenberg H, Reynisdottir S, et al. J Clin Endocrinol Metab 1997; 82: 159-166.
19. Hansson P, Nordin G, Nilsson P. Biochem Biophys Acta 1983; 735: 364-371.
20. Tribble DL, Chu BM, Levine GA, Krauss RM and Gong EL. Arterioscl Thromb Vasc Biol 1996; 16:1580-1587.
21. Hippeli S and Elstner EF. FEBS letters 1996; 443: 1-7.